Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News SAB Biotherapeutics Inc SABSW


Primary Symbol: SABS

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other... see more

Current News (NDAQ:SABS)

SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management

GlobeNewswire 2 days ago

SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights

GlobeNewswire November 13, 2025

SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142

GlobeNewswire November 4, 2025

SAB BIO to Participate in Upcoming Investor Conferences

GlobeNewswire November 4, 2025

SAB BIO Highlights Data in Multiple Presentations at EASD

GlobeNewswire September 19, 2025

SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes

GlobeNewswire September 3, 2025

SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates

GlobeNewswire August 7, 2025

SAB BIO Announces Oversubscribed $175 Million Private Placement

GlobeNewswire July 21, 2025

SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

GlobeNewswire May 9, 2025
View More News ››

Opinion & Analysis (NDAQ:SABS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:SABS)

RE:SABS....trading at $3.40 now

Looked at my stock ticker yesterday morning. Stock at over $5 but dropping. Managed to sell for $4.32. Dropped that much in just the...
UnknownUnknowns - July 23, 2025

SABS....trading at $3.40 now

Did somebody say FOMO????
Iseneschal - July 21, 2025

RE:SABS....1st scalp of the a.m on the NR

SABS is buying me lunch today. Cheers !!!! No FOMO for this Cowboy
Iseneschal - July 21, 2025

Buy buddy buy because it's taking off this morning.

Otherwise FOMO for you fellas out there today anyway so good luck to all of you guys
coolfooldumbguy - July 21, 2025

SABS....1st scalp of the a.m on the NR

Lunch money works for me ; )
Iseneschal - July 21, 2025

Sheesh!

Where is everybody?  People should be discussing this one.  Technicals are lining up nicely.  Just waiting for my trigger...
dragshot - June 1, 2023
View more Bullboard ››

Blue Sky Uranium Corp.

Blue Sky Uranium Corp.

Blue Sky Uranium Corp., a junior uranium exploration company, engages in the acquisition, exploration, and evaluation of ...
View More »